Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday. Other equities research analysts also recently issued research reports about the company. Bank of America dropped their target price on Ascendis Pharma A/S from $132.00 […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating)‘s stock had its “maintains” rating reissued by equities research analysts at 3M in a report released on Friday, Benzinga reports. A number of other research analysts also recently issued reports on the stock. Oppenheimer downgraded shares of Ascendis Pharma A/S from an “outperform” rating to a “market perform” […]
3M reaffirmed their maintains rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) in a research note issued to investors on Friday morning, Benzinga reports. Several other research analysts also recently commented on ASND. Cantor Fitzgerald increased their price objective on Ascendis Pharma A/S from $142.00 to $152.00 in a research note on […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating)‘s stock had its “maintains” rating reissued by 3M in a research report issued to clients and investors on Friday, Benzinga reports. A number of other research analysts have also issued reports on ASND. Cantor Fitzgerald boosted their price target on Ascendis Pharma A/S from $142.00 to $152.00 in […]